Navigation Links
FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals' MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
Date:8/1/2011

CAMBRIDGE, Mass., Aug. 1, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted MM-398 orphan drug status for the treatment of pancreatic cancer. MM-398 is a novel, stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan.  MM-398 is partnered with PharmaEngine, Inc. for development and commercialization in Taiwan under the designation PEP02.

(Logo:  http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

One of the purposes of the Orphan Drug Designation program is to provide orphan status to drugs and biologics intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the United States.  In the United States, the company that first obtains FDA approval for a designated orphan drug for the specified rare disease or disorder receives orphan drug marketing exclusivity for that drug for a period of seven years. This orphan drug exclusivity prevents the FDA from approving another application, including a full new drug application (NDA), to market the same drug for the same orphan indication, except in very limited circumstances.  Orphan drug designation in the United States also provides for a reduction in regulatory fees and additional regulatory support for research and development initiatives.

About PharmaEngine, Inc.

PharmaEngine is a biopharmaceutical company established in Taipei, Taiwan in 2003.  The company focuses on the development of new drugs to treat cancer and Asian prevalent diseases.  For further information on PharmaEngine, please visit the Company's website at http://www.pharmaengine.com.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.  Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by the end of 2011.

Contact:  Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, betsy@raymondstevenson.com


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. UCLA Receives Six UC Health Quality Grants to Improve Hospital Care
2. China Grants COPAN Patent for Flocked Swabs
3. Edison Pharmaceuticals Announces FDA Grants EPI-743 Orphan Drug Designation
4. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5. FDA Formally Accepts Dune Medicals MarginProbe™ System Pre-Market Approval (PMA) Application and Grants Expedited Review Status
6. FDA Grants Orphan Drug Designation for Mithridions MCD-386CR to Treat Progressive Supranuclear Palsy
7. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
8. FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
9. FDA Grants 510(k) Clearance to Life Technologies Stem Cell Growth Medium
10. Court Grants Preliminary Approval to Class Action Settlement that Provides Benefits Of Approximately $20 Million to Healthcare Providers that Purchased a SS1 Before January 1, 2009
11. Sequenom Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... ... , ... In the United States, single-family home owners pay ... York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 a ... rates, which contributes to the relatively lower cost of living in places like ...
Breaking Medicine News(10 mins):